Survival
Three patients in the SOC group had shorter follow-up than the required 6 months for the primary end point, due to the early termination of the study. There was no significant difference in the primary outcome, namely survival at 6 months after randomization, with 62% (26 of 42 patients) alive in the SOC group compared with 44% (19 of 43 patients) in the group treated with SOC plus disulfiram and copper (